These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 9639745

  • 1. [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome].
    Wu X, Gu Q, Su Y.
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):489-91. PubMed ID: 9639745
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome].
    Zironi C, Pantaleoni M, Zizzo G, Coletta F, Velardo A.
    Minerva Ginecol; 1991 Oct; 43(10):443-7. PubMed ID: 1685015
    [Abstract] [Full Text] [Related]

  • 3. [Functional states of pituitary-ovary, adrenal and thyroid axes in women with polycystic ovarian syndrome].
    Wu X, Zhang Z, Su Y.
    Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):153-6. PubMed ID: 10682483
    [Abstract] [Full Text] [Related]

  • 4. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.
    Prelević GM, Würzburger MI, Perić LA.
    J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696
    [Abstract] [Full Text] [Related]

  • 5. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
    Filho RB, Domingues L, Naves L, Ferraz E, Alves A, Casulari LA.
    Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
    [Abstract] [Full Text] [Related]

  • 6. [The effects of l-dopa administration on the prolactin levels in short-stature subjects].
    Saggese G, Cesaretti G, Carlotti C, Cioni C, Bracaloni C.
    Minerva Pediatr; 1992 Mar; 44(3):73-8. PubMed ID: 1518496
    [Abstract] [Full Text] [Related]

  • 7. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF, Li X, Zhu MW.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [Abstract] [Full Text] [Related]

  • 8. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
    Parsanezhad ME, Alborzi S, Jahromi BN.
    Int J Fertil Womens Med; 2002 Oct; 47(6):272-7. PubMed ID: 12570169
    [Abstract] [Full Text] [Related]

  • 9. [Effect of growth hormone on the outcome of ovulation induction in patients with polycystic ovary syndrome].
    Wang Y, Li M, Yang C.
    Zhonghua Fu Chan Ke Za Zhi; 2001 Jan; 36(1):36-9. PubMed ID: 11778543
    [Abstract] [Full Text] [Related]

  • 10. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Hsu MI, Liou TH, Liang SJ, Su HW, Wu CH, Hsu CS.
    Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
    [Abstract] [Full Text] [Related]

  • 11. [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
    Liu ZA, Xue YM, Chen LX, Cai Q, Chen H, Zhang J, Cui QH, Ge J, Yuan T.
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):586-90. PubMed ID: 15498183
    [Abstract] [Full Text] [Related]

  • 12. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients.
    Esel E, Kartalci S, Tutus A, Turan T, Sofuoglu S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):303-9. PubMed ID: 14751427
    [Abstract] [Full Text] [Related]

  • 13. Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arthritis and ankylosing spondylitis.
    Rovensky J, Imrich R, Malis F, Zlnay M, Macho L, Koska J, Vigas M.
    J Rheumatol; 2004 Dec; 31(12):2418-21. PubMed ID: 15570644
    [Abstract] [Full Text] [Related]

  • 14. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS.
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.
    Lee EJ, Lee BS, Lee HC, Park KH, Song CH, Huh KB.
    Fertil Steril; 1993 Jul; 60(1):53-7. PubMed ID: 8513959
    [Abstract] [Full Text] [Related]

  • 16. [Lipoprotein lipids in polycystic ovarian syndrome: independent associations with androgen excess and insulin resistance].
    Wu X, Zhang Z, Su Y.
    Zhonghua Fu Chan Ke Za Zhi; 1998 Jan; 33(1):25-7. PubMed ID: 10682453
    [Abstract] [Full Text] [Related]

  • 17. Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women.
    Shi Y, Gao X, Sun X, Zhang P, Chen Z.
    Fertil Steril; 2008 Oct; 90(4):1139-43. PubMed ID: 17889857
    [Abstract] [Full Text] [Related]

  • 18. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM, Würzburger MI, Perić LA.
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [Abstract] [Full Text] [Related]

  • 19. Serum resistin levels in women with polycystic ovary syndrome.
    Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D.
    Fertil Steril; 2004 Feb; 81(2):361-6. PubMed ID: 14967374
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone secretion and insulin-like growth factor-1 are related to hyperandrogenism in nonobese patients with polycystic ovary syndrome.
    Premoli AC, Santana LF, Ferriani RA, Moura MD, De Sá MF, Reis RM.
    Fertil Steril; 2005 Jun; 83(6):1852-5. PubMed ID: 15950665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.